SCHEMBL286228

SCHEMBL286228

CCCCc1noc(C)c1COc1ncc(C(=O)OCC(N)=O)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
L3MBTL1 Q9Y468 5/20 0.35
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
LMNA P02545 2/20 0.32
TSHR P16473 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL286096 0.86 KMT2A (0.39) ALDH1A1L3MBTL1GAAKMT2ASMN1; SMN2
SCHEMBL2749182 0.85 GAA (0.40) ALDH1A1L3MBTL1GAASMN1; SMN2LMNA
SCHEMBL285759 0.82 GABRA5 (0.41) L3MBTL1GABRA5
SCHEMBL285760 0.80 SLC8A1 (0.41) L3MBTL1POLBGABRA5
SCHEMBL286095 0.79 GABRA5 (0.43) L3MBTL1GABRA5
SCHEMBL286071 0.79 GABRA5 (0.41) L3MBTL1GABRA5
SCHEMBL286047 0.79 CDC7 (0.34) ALDH1A1L3MBTL1CDC7DBF4SMN1; SMN2
SCHEMBL286248 0.79 GABRA5 (0.51) GABRA5
SCHEMBL286463 0.77 ALDH1A1 (0.34) ALDH1A1L3MBTL1GAAMEN1KMT2A
SCHEMBL286143 0.76 ALDH1A1 (0.35) ALDH1A1L3MBTL1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed